Current oncology最新文献

{"title":"Sleep Problems and Quality of Life in Breast Cancer Patients.","authors":"Andreas Hinz, Michael Friedrich, Thomas Schulte, Mareike Ernst, Ana N Tibubos, Katja Petrowski, Nadja Dornhöfer","doi":"10.3390/curroncol32090508","DOIUrl":"10.3390/curroncol32090508","url":null,"abstract":"<p><strong>Background: </strong>Sleep problems are frequently observed in breast cancer patients. However, the relationship between sleep quality and overall quality of life (QoL) and the specificity of different sleep-related questionnaires have not yet been adequately studied in breast cancer patients.</p><p><strong>Methods: </strong>The sample of this cross-sectional study consisted of 533 breast cancer patients, recruited in a German rehabilitation clinic, with a mean age of 52.3 years (SD = 12.5 years). The following three sleep-related questionnaires were used: the Pittsburgh Sleep Quality Index (PSQI), the Insomnia Severity Index (ISI), and the Jenkins Sleep Scale (JSS). In addition, we used the QoL instrument EORTC QLQ-C30.</p><p><strong>Results: </strong>Sleep quality was poor in this sample of breast cancer patients. The effect sizes <i>d</i>, indicating the difference in sleep quality between the patient sample and the general population, were between 0.97 and 1.76 (<i>p</i> < 0.001). QoL was impaired in all components (<i>p</i> < 0.001); the impairment in the dimension of sleep quality (<i>d</i> = 1.70) was among the highest. Sleep quality was correlated with all components of QoL. The comparison of the three sleep-related questionnaires showed that the results obtained in oncological studies partly depend on the instrument used.</p><p><strong>Conclusion: </strong>As the burden of sleep problems is high, screening for sleep problems in breast cancer patients is important.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dissociation Between Tumor Response and PTTM Progression During Entrectinib Therapy in NTRK Fusion-Positive Colon Cancer.","authors":"Hideki Nagano, Shigekazu Ohyama, Atsushi Sato, Jun Igarashi, Tomoko Yamamoto, Mikiko Kobayashi","doi":"10.3390/curroncol32090506","DOIUrl":"10.3390/curroncol32090506","url":null,"abstract":"<p><p>We report a rare case of pulmonary tumor thrombotic microangiopathy (PTTM) in a patient with metastatic neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive transverse colon cancer who exhibited a marked radiologic and biochemical response to entrectinib. Despite significant tumor shrinkage, progressive dyspnea and hypoxemia developed approximately four weeks after therapy initiation. Chest CT revealed diffuse interstitial infiltrates, initially interpreted as drug-induced pneumonitis or infection. Entrectinib was discontinued, but respiratory failure progressed, and the patient died shortly thereafter. Autopsy revealed widespread pulmonary microangiopathy with fibrocellular intimal proliferation and tumor emboli in small pulmonary arteries, consistent with PTTM. Notably, no hematogenous metastases were identified; instead, tumor spread appeared to occur via an atypical lymphatic route through the thoracic duct. The tumor exhibited microsatellite stability and a modest mutation burden, suggesting that lymphatic dissemination and microvascular pathology may progress independently of these genomic features. This case underscores a critical dissociation between oncologic response and vascular complications, indicating that tropomyosin receptor kinase (TRK) inhibitor monotherapy may be insufficient to prevent PTTM. Comprehensive management may require concurrent strategies targeting the pulmonary microvasculature, including antiangiogenic therapy and modulation of cytokine and growth factor signaling.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Participants' Perceptions of Advantages and Drawbacks of \"Drop-In\" Versus \"Closed-Group\" Formats Related to Cancer Bereavement Program Delivery.","authors":"Yoojung Kim, Carmen G Loiselle","doi":"10.3390/curroncol32090505","DOIUrl":"10.3390/curroncol32090505","url":null,"abstract":"<p><p>Having opportunities to readily access bereavement support for people affected by the death of a loved one is central to any comprehensive approach to cancer care. <i>Hope & Cope</i>, a community-based cancer support organization in Montreal, Quebec, Canada, offers professional- and volunteer-led bereavement programs in two formats: \"drop-in\" (open as needed) and \"closed-group\" (structured). This qualitative study explored contributions and potential drawbacks of these two-program delivery formats as reported by bereaved participants (<i>N</i> = 18). Semi-structured individual interviews were conducted according to groups: Drop-in (<i>n</i> = 7) and closed-group (<i>n</i> = 11). Audio-recorded interviews (lasting between 30 and 60 min) were transcribed verbatim. Data were analyzed using thematic analysis. Three themes were revealed: (1) Program structure according to grief timeline, (2) Flexibility in the choice of topics and impact on grief experiences, (3) Grief support dynamics in relation to group composition. Findings indicate that drop-in provided \"as-needed\" tailored support, whereas closed-groups ensured consistency in attendance. Some drawbacks included high attendance turnover in the drop-in and less relevant topics in the structured closed format. Supportive interventions should continue to be tailored to people's profiles and preferences, not only for content but also for delivery formats.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy.","authors":"Yunus Emre Altıntaş, Oğuzcan Kınıkoğlu, Deniz Işık, Aziz Batu, Ayberk Bayramgil, Büşra Niğdelioğlu, Uğur Özkerim, Sıla Öksüz, Heves Sürmeli, Nedim Turan, Hatice Odabaş","doi":"10.3390/curroncol32090503","DOIUrl":"10.3390/curroncol32090503","url":null,"abstract":"<p><strong>Background: </strong>Hormone receptor-positive (HR+), HER2- negative metastatic breast cancer (MBC) is the most common subtype of advanced breast cancer. Resistance to endocrine therapy often develops, particularly after CDK4/6 inhibitors. Everolimus, an mTOR inhibitor, may restore hormone sensitivity, but real-world data after CDK4/6 and chemotherapy are limited.</p><p><strong>Methods: </strong>This retrospective, single-center study included 70 patients with HR+/HER2- MBC who progressed on CDK4/6 inhibitors and at least one line of chemotherapy. All received daily oral everolimus (10 mg) plus exemestane (25 mg). Tumor response was assessed via RECIST v1.1, and survival outcomes were estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>Median progression-free survival was 6.6 months and overall survival was 22.6 months. The disease control rate was 88.6%, with 57.1% showing partial response. Fatigue (20%), skin toxicity (8.6%), and stomatitis (5.7%) were the most common adverse events. No grade 3-4 toxicities or discontinuations occurred. No clinical or pathological variables significantly influenced survival.</p><p><strong>Conclusions: </strong>Everolimus plus exemestane provided meaningful clinical benefit and manageable toxicity in heavily pretreated HR+/HER2- MBC patients. This regimen remains a valid later-line option, particularly in settings with limited access to newer targeted therapies or genomic testing.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten-Year Real-World Outcomes and Clinicopathologic Predictors of Recurrence in Adult Granulosa Cell Tumors: A Turkish Single-Center Experience.","authors":"Aslı Geçgel, Oğuzcan Özcan, Pınar Peker, Gürdeniz Serin, Burçak Karaca Yayla, Erdem Göker, Ulus Ali Şanlı","doi":"10.3390/curroncol32090504","DOIUrl":"10.3390/curroncol32090504","url":null,"abstract":"<p><p>Adult granulosa cell tumors (AGCT) are rare ovarian neoplasms with typically indolent behavior but potential for late recurrence. This study aimed to evaluate long-term outcomes and identify clinicopathological predictors of disease-free survival (DFS) in patients with AGCTs. This retrospective cohort study included patients with histologically confirmed AGCTs who were treated or followed at Ege University Faculty of Medicine between January 2012 and 2023. Survival outcomes were analyzed using Kaplan-Meier and Cox regression methods. Among 55 patients with a median follow-up of 113.7 months, the median DFS was 92.3 months, and the median overall survival (OS) was 113.7 months. The 5-year DFS and OS rates were 84.5% and 93.9%, respectively. Recurrence occurred in 23.6% of patients and was significantly linked to advanced FIGO stage, atypical endometrial pathology, and bleomycin-etoposide-cisplatin (BEP)/etoposide-cisplatin (EP)-based adjuvant chemotherapy. Larger tumor size (>10 cm) and stage III disease were also associated with shorter DFS. Univariate analysis showed that stage III disease (HR 7.14, <i>p</i> = 0.006) and tumor size >10 cm (HR 3.59, <i>p</i> = 0.025) were associated with significantly shorter DFS, while absence of endometrial pathology was protective (HR 0.34, <i>p</i> = 0.022). In multivariate analysis, stage III disease remained the only independent predictor of recurrence (HR 4.45, <i>p</i> = 0.046). Advanced-stage disease is an independent predictor of recurrence and should be considered a high-risk feature requiring prolonged follow-up.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social Networks of Adolescents and Young Adults with Cancer: A Cross-Sectional Study.","authors":"Rohini R Datta, Bojana Petrovic, Argerie Tsimicalis, A Fuchsia Howard, Emily K Drake, Sheila N Garland, Karine Chalifour, Norma M D'Agostino, Abha A Gupta, Jacqueline L Bender","doi":"10.3390/curroncol32090502","DOIUrl":"10.3390/curroncol32090502","url":null,"abstract":"<p><p>A cancer diagnosis disrupts the social networks of adolescents and young adults (AYAs), impacting their overall health and wellbeing. This cross-sectional study examined the social network integration (SNI; size and frequency of contact) of AYAs with cancer in Canada. A survey was distributed to AYAs with cancer at an urban cancer centre and across Canada (n = 334). SNI was measured with the Berkman-Syme Social Network Index (SNI) and a modified version accounting for online interactions (SNI+). A multivariable logistic regression analysis was performed to identify factors associated with SNI and SNI+. A total of 54.8% and 68% of AYAs with cancer were classified as socially integrated with each measure, respectively. Living with others was associated with greater SNI and SNI+ (SNI OR = 3.27, 95% CI = 1.39, 7.72; SNI+ OR = 2.52, 95% CI = 1.14, 5.58), and an annual personal income of >CAD 80,000 was associated with greater SNI+ (SNI+ OR = 2.92, 95% CI = 1.09, 7.77). A significant proportion of AYAs with cancer are socially isolated. AYAs with cancer who live alone and whose personal income is less than CAD 80,000 are at a higher risk of social isolation. Digital technology could be leveraged to increase the SNI of AYAs with cancer.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'What Really Goes on in My Cancer Bubble, They Cannot Understand': Social Functioning Among Adolescent and Young Adult (AYA) Cancer Patients.","authors":"Sophia H E Sleeman, Milou J P Reuvers, Michaela H van der Veldt, Eveliene Manten-Horst, Olga Husson","doi":"10.3390/curroncol32090501","DOIUrl":"10.3390/curroncol32090501","url":null,"abstract":"<p><p>Cancer during adolescence and young adulthood (AYA; 18-39 years) can disrupt age-related milestones and impair social functioning. Many AYA patients report unmet social support needs and relationship changes, leading to isolation. This mixed-methods study explores social challenges among AYA patients actively seeking support through a communication tool, the 'AYA Match app', supporting communication with loved ones. Upon downloading the app, participants completed questionnaires on social support (MOS-SSS) and social functioning (EORTC CAT) and open-ended questions about social challenges. Eligibility included a first cancer diagnosis at AYA age and fluency in Dutch. The findings show that cancer negatively affected AYA patients' social functioning. Physical limitations and difficulty relating to peers caused isolation and feelings of loneliness. Some preferred solitude or withheld emotions to protect loved ones. Challenges included forming new relationships, feeling left behind as peers reach milestones, and struggling with a changed life perspective. Participants with children reported less social support. This study highlights the complex social challenges AYA cancer patients face. While support from loved ones is crucial, it may not always be effective. Personalized interventions like peer support, improved family communication, and tailored digital tools are needed to improve social well-being and quality of life in AYAs with cancer.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis.","authors":"Ruchira V Mahashabde, Sajjad A Bhatti, Bradley C Martin, Jacob T Painter, Mausam Patel, Analiz Rodriguez, Jun Ying, Chenghui Li","doi":"10.3390/curroncol32090499","DOIUrl":"10.3390/curroncol32090499","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) display efficacy in non-small cell lung cancers (NSCLCs) with brain metastases (BMs) and studies suggest potential synergy with cranial radiation (CR). However, population-based evaluations of optimal time between ICI-CR combinations are limited in the US. Using SEER-Medicare database (2010-2019), we analyzed patients aged ≥65 years with NSCLC and BM receiving ICI-CR within 6 months of diagnosis, excluding those receiving targeted therapies. First treatment after diagnosis (ICI or CR) was defined as index treatment; followed by subsequent treatment. Findings were validated using an independent cohort from the TriNetX LIVE™ Platform. Patients were grouped by interval between the end of the index treatment and the start of the subsequent treatment: ≤15 days (n = 117), 16-30 days (n = 42), and >30 days (n = 77). Overall survival (OS) was measured from the start of the subsequent treatment until death, end of insurance coverage, or study end. Kaplan-Meier survival curves and multivariable Cox proportional hazards models estimated differences between groups. Among 236 patients, median OS was 134 days, 92 days, and 209 days, respectively. No significant OS differences were found across intervals. However, a survival benefit emerged approximately 300 days after follow-up when ICI was administered within 15 days of CR. These findings offer insight into treatment sequencing in NSCLC with BM and support further investigation in larger cohorts.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Retroperitoneal Mucinous Cystadenocarcinoma in a Male Patient: A Case Report.","authors":"Masayuki Tomioka, Keita Nakane, Koji Iinuma, Kota Kawase, Tomoki Taniguchi, Yuki Tobisawa, Aoi Muto, Tomohiro Kanayama, Tatsuhiko Miyazaki, Takuya Koie","doi":"10.3390/curroncol32090500","DOIUrl":"10.3390/curroncol32090500","url":null,"abstract":"<p><p>Primary retroperitoneal mucinous cystadenocarcinoma (PRMC) is an uncommon malignant neoplasm with few reported cases, particularly among male patients. Currently, only nine documented cases have been reported worldwide, including the present case. The present case report describes the incidental detection of PRMC in an 86-year-old male patient. Despite being offered surgical intervention, the patient initially opted against treatment. Consequently, follow-up imaging examinations were performed for 3 subsequent years. The tumor, initially measuring 31 × 32 × 31 mm, gradually increased to 58 × 60 × 59 mm. Subsequently, the patient underwent laparoscopic retroperitoneal tumor resection. Histopathological examination revealed adenocarcinoma characterized by intestinal differentiation. The patient has exhibited no evidence of disease for 1 year postoperatively. The present case is noteworthy, as this disease rarely occurs in men, thereby offering significant potential for educational and scientific contributions. Notably, the patient's age, longitudinal observation of tumor progression through imaging over a period of 3 years, and complete surgical excision of the tumor are salient features of this case. These findings may prove useful in the diagnosis and treatment strategy for male patients with PRMC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trend and Cancer-Specific Prevalence of Kidney Stones Among US Cancer Survivors, 2007-2020.","authors":"Chao Cao, Ruixuan Wang, Xiangren Wang, Mohammad Abufaraj, Thomas Waldhoer, Geoffrey T Gotto, Shahrokh F Shariat, Lin Yang","doi":"10.3390/curroncol32090498","DOIUrl":"10.3390/curroncol32090498","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the prevalence and cancer-specific patterns of kidney stones among U.S. cancer survivors compared to non-cancer adults. <b>Methods:</b> This was a serial cross-sectional, descriptive epidemiologic analysis of a US nationally representative sample from the National Health and Nutrition Examination Survey from 2007 to 2020. Weighted prevalence of kidney stones was estimated for both non-cancer adults and cancer survivors by study cycle. Multivariable logistic regression was conducted to examine factors associated with higher probability of kidney stones in both non-cancer adults and cancer survivors. <b>Results:</b> From 2007-2008 to 2017-2020, kidney stone prevalence rose in both non-cancer adults (8.5% to 9.2%, <i>p</i> for trend = 0.013) and cancer survivors (13.1% to 17.3%, <i>p</i> for trend = 0.033). Throughout the study period, prevalence was consistently higher in cancer survivors. The overall prevalence from 2007 to 2020 was 15.8% (95% CI: 14.0-17.5%) in cancer survivors and 9.2% (95% CI: 8.8-9.6%) in non-cancer adults. After adjusting for sociodemographic, lifestyle, and health factors, cancer survivors had higher odds of kidney stones (OR = 1.28, 95% CI: 1.10-1.49). Compared with non-cancer adults, survivors of ovarian (OR = 3.71, 95% CI: 1.77-7.78), kidney (OR = 2.88, 95% CI: 1.46-5.68), bone and soft tissue (OR = 2.86, 95% CI: 1.12-7.30), uterine (OR = 1.94, 95% CI: 1.17-3.22), cervix (OR = 1.68, 95% CI: 1.08-2.61) and prostate (OR = 1.41, 95% CI: 1.06-1.87) cancers were statistically more likely to report kidney stones. The prevalence was numerically highest among survivors of kidney cancer (34.7%), followed by bone and soft tissue (29.9%), ovarian (29.8%), and testicular (26.3%) cancers. <b>Conclusions:</b> The higher prevalence of kidney stones in cancer survivors, with substantial variation by cancer type, highlights the urgent need for effective clinical management of kidney stones in oncology settings and mechanistic research.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}